On Oct. 30, 2018, Pascal Biosciences announced the Company had entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop a cannabinoid-based product for the treatment of glioblastoma multiform and brain metastases.

The program, developed in the lab of renowned cannabis researcher Dr. Nephi Stella, founder and co-director of the UW Center for Cannabis Research, included a lead therapeutic, ST-403. Pascal planned to begin human clinical studies of ST-403 in 2019.